Cargando…
Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
Adeno-associated virus (AAV) vector-based gene therapy is currently the only in vivo gene therapy approved in the US and Europe. The recent tragic death of three children in a clinical trial to treat X-Linked Myotubular Myopathy by delivering myotubularin with an AAV8 vector notwithstanding, AAV rem...
Autor principal: | Weber, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010240/ https://www.ncbi.nlm.nih.gov/pubmed/33815421 http://dx.doi.org/10.3389/fimmu.2021.658399 |
Ejemplares similares
-
Immunogenicity and toxicity of AAV gene therapy
por: Ertl, Hildegund C. J.
Publicado: (2022) -
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020) -
T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021) -
Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021) -
Editorial: Immunogenicity and toxicity of AAV gene therapy
por: Bradbury, Allison, et al.
Publicado: (2023)